Tumour Models Summit Nordics on April 09-10, 2025 in Stockholm, Sweden

The inherent heterogeneity of cancer - both inter-patient and intra-tumoral – remains a significant challenge in cancer modeling. With only 5% of cancer drugs successfully advancing to clinical trials, there is a critical need for more accurate and predictive models to guide therapeutic development.

For the first time, the Tumour Models Summit Nordics unites pharma, biotech, and research leaders across the thriving Nordic biotech ecosystem to tackle this challenge head-on. As the region's only industry-led event of its kind, this summit provides a rare opportunity to connect with top experts in preclinical and translational research.

Gain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling, discover strategies to de-risk your studies, and learn how to refine your drug development pipeline. Join us to engage with decision-makers, explore ground breaking solutions, and accelerate the path from lab to patient in today's rapidly evolving landscape.

URLs:

Tickets: https://go.evvnt.com/2798299-1?pid=10008

Brochure: https://go.evvnt.com/2798299-3?pid=10008

Price:
Free: SEK 0.00

Speakers: Adam Robertson, Chief Scientific Officer, Hemispherian, Carl Sandén, Chief Scientific Officer, Lead Biologics, Ditte Boilesen, Chief Executive Officer, Loma Therapeutics, Floriana Cremasco, Senior Scientist, Roche, Irena Adkins, Director of Pharmacology, SOTIO Biotech a.s., Jakub Swiercz, Vice President of Research and Development, Alesta Therapeutics, Jette Lange, Director of Non-Clinical Department, ADCendo, Krzysztof Brzozka, Chief Scientific Officer, Ryvu Therapeutics, Lasse Neukirch, Cancer Vaccine Researcher, Hervolution Therapeutics, Linda Mårtensson, Senior Research Scientist, BioInvent, Lucas Arrudam Chief Scientific Officer, CuraCell, Mette Trauelsen, Chief Executive Officer, SOLID Therapeutics, Reagan Jarvis, Chief Executive Officer, Anocca AB, Robin Loving, Chief Scientific Officer, Salipro Biotech AB, Santiago Parpal Tamburini, Principal Scientist, Sprint Bioscience, Thomas F. Baumert, MD Founder, Alentis Therapeutics, Tomasz Grabowski, Head of Preclinical Development, JJP Biologics

Time: 08:00 to 17:00